Milestone Pharmaceuticals (NASDAQ:MIST) on Friday reported a wider net loss for the third quarter and announced cost-cutting measures.
Milestone Pharmaceuticals reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 21 cents per share. The company reported quarterly sales of $2.963 million which beat the analyst consensus estimate of $1.143 million.
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses. Importantly, we expect these measures to extend our cash runway beyond the anticipated Phase 3 readout of ReVeRA-301 in the second half of 2028.”
Milestone Pharmaceuticals shares fell 14.4% to trade at $0.4449 on Monday.
These analysts made changes to their price targets on Milestone Pharmaceuticals following earnings announcement.
- HC Wainwright & Co. analyst Brandon Folkes maintained the stock with a Buy and lowered the price target from $8 to $6.
- Piper Sandler analyst Edward Tenthoff maintained the stock with an Overweight rating and cut the price target from $7 to $3.
- TD Cowen analyst Ritu Baral maintained the stock with a Buy and lowered the price target from $8 to $5.
Considering buying MIST stock? Here’s what analysts think:

Photo via Shutterstock
Comments